124 related articles for article (PubMed ID: 35256754)
1. The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
Tomiczek-Szwiec J; Szwiec M; Falco M; Cybulski C; Wokolorczyk D; Jakubowska A; Gronwald J; Stawicka M; Godlewski D; Kilar E; Marczyk E; Siołek M; Wiśniowski R; Haus O; Sibilski R; Bodnar L; Sun P; Narod SA; Lubinski J; Huzarski T;
Br J Cancer; 2022 Jul; 127(1):84-91. PubMed ID: 35256754
[TBL] [Abstract][Full Text] [Related]
2. Survival from breast cancer in patients with CHEK2 mutations.
Huzarski T; Cybulski C; Wokolorczyk D; Jakubowska A; Byrski T; Gronwald J; Domagała P; Szwiec M; Godlewski D; Kilar E; Marczyk E; Siołek M; Wiśniowski R; Janiszewska H; Surdyka D; Sibilski R; Sun P; Lubiński J; Narod SA
Breast Cancer Res Treat; 2014 Apr; 144(2):397-403. PubMed ID: 24557336
[TBL] [Abstract][Full Text] [Related]
3. Survival of bladder or renal cancer in patients with CHEK2 mutations.
Złowocka-Perłowska E; Dębniak T; Słojewski M; van de Wetering T; Tołoczko-Grabarek A; Cybulski C; Scott RJ; Lubiński J
PLoS One; 2021; 16(9):e0257132. PubMed ID: 34499690
[TBL] [Abstract][Full Text] [Related]
4. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
5. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
6. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
Huzarski T; Byrski T; Gronwald J; Górski B; Domagala P; Cybulski C; Oszurek O; Szwiec M; Gugala K; Stawicka M; Morawiec Z; Mierzwa T; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siolek M; Surdyka D; Wisniowski R; Posmyk M; Sun P; Lubinski J; Narod SA
J Clin Oncol; 2013 Sep; 31(26):3191-6. PubMed ID: 23940229
[TBL] [Abstract][Full Text] [Related]
7. The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
Huzarski T; Byrski T; Gronwald J; Cybulski C; Oszurek O; Szwiec M; Gugała K; Stawicka M; Morawiec Z; Mierzwa T; Falco M; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siołek M; Surdyka D; Wiśniowski R; Posmyk M; Domagała P; Sun P; Lubiński J; Narod SA;
Breast Cancer Res Treat; 2016 Apr; 156(2):371-8. PubMed ID: 26983446
[TBL] [Abstract][Full Text] [Related]
8. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
Liu Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
BMC Cancer; 2015 Mar; 15():194. PubMed ID: 25884806
[TBL] [Abstract][Full Text] [Related]
9. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
Kriege M; Hollestelle A; Jager A; Huijts PE; Berns EM; Sieuwerts AM; Meijer-van Gelder ME; Collée JM; Devilee P; Hooning MJ; Martens JW; Seynaeve C
Br J Cancer; 2014 Aug; 111(5):1004-13. PubMed ID: 24918820
[TBL] [Abstract][Full Text] [Related]
10. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.
Leedom TP; LaDuca H; McFarland R; Li S; Dolinsky JS; Chao EC
Cancer Genet; 2016 Sep; 209(9):403-407. PubMed ID: 27751358
[TBL] [Abstract][Full Text] [Related]
12. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
13. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Tung N; Armel S; Senter L; Singer CF; Fruscio R; Couch F; Weitzel JN; Karlan B; Foulkes WD; Moller P; Eisen A; Ainsworth P; Neuhausen SL; Olopade O; Sun P; Gronwald J; Narod SA;
Breast Cancer Res Treat; 2019 Jun; 175(2):443-449. PubMed ID: 30756284
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Rebbeck TR; Levin AM; Eisen A; Snyder C; Watson P; Cannon-Albright L; Isaacs C; Olopade O; Garber JE; Godwin AK; Daly MB; Narod SA; Neuhausen SL; Lynch HT; Weber BL
J Natl Cancer Inst; 1999 Sep; 91(17):1475-9. PubMed ID: 10469748
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.
Meyer A; Dörk T; Sohn C; Karstens JH; Bremer M
Radiother Oncol; 2007 Mar; 82(3):349-53. PubMed ID: 17250914
[TBL] [Abstract][Full Text] [Related]
17. A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.
Liu Y; Liao J; Xu Y; Chen W; Liu D; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu X; Xie Y
Hum Mutat; 2011 Sep; 32(9):1000-3. PubMed ID: 21618645
[TBL] [Abstract][Full Text] [Related]
18. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
19. CHEK2 mutations and the risk of papillary thyroid cancer.
Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
[TBL] [Abstract][Full Text] [Related]
20. Predictors of survival for breast cancer patients with a BRCA1 mutation.
Narod SA; Huzarski T; Gronwald J; Byrski T; Marczyk E; Cybulski C; Szwiec M; Wisniowski R; Birkenfeld B; Kilar E; Sibilski R; Sun P; Lubinski J
Breast Cancer Res Treat; 2018 Apr; 168(2):513-521. PubMed ID: 29247441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
